FDA, PhRMA Liver Toxicity Meeting Will Consider Postmarketing Surveillance

FDA and the Pharmaceutical Research & Manufacturers of America will discuss new mechanisms for detecting liver toxicity during postmarketing surveillance at a joint workshop on drug-induced liver injury Feb. 12-13.